Comparative Pharmacology
Head-to-head clinical analysis: KYNAMRO versus OMACOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KYNAMRO versus OMACOR.
KYNAMRO vs OMACOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the mRNA of apolipoprotein B-100 (apoB-100), inhibiting its translation and reducing the production of apoB-100-containing lipoproteins, including LDL, VLDL, and Lp(a).
Omega-3-acid ethyl esters (EPA and DHA) reduce hepatic triglyceride synthesis by inhibiting acyl-CoA:1,2-diacylglycerol acyltransferase and increasing beta-oxidation. They also decrease very-low-density lipoprotein (VLDL) secretion and enhance triglyceride clearance from circulating VLDL particles.
Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.
4 g orally once daily or 2 g orally twice daily, taken with meals. Each capsule contains 1 g of omega-3-acid ethyl esters (approximately 465 mg eicosapentaenoic acid and 375 mg docosahexaenoic acid).
None Documented
None Documented
Terminal elimination half-life is approximately 28-31 days (range 21-40 days) in patients with homozygous familial hypercholesterolemia, supporting weekly subcutaneous dosing.
Terminal elimination half-life: ~55–75 hours for EPA and DHA (beta-phase). Clinical context: steady-state achieved after 4–8 weeks; half-life supports once-daily dosing.
Primarily hepatobiliary elimination; less than 1% excreted unchanged in urine. Mipomersen is metabolized by endonucleases and exonucleases to shorter oligonucleotides, which are excreted in bile and feces.
Primarily fecal as unchanged drug and metabolites; <5% renal. Biliary excretion accounts for ~90% of elimination via feces, with minimal urinary excretion (0.5–2%).
Category C
Category C
Antilipemic
Antilipemic